DexCom, Inc. (DXCM) - Q1 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2026. DexCom, Inc. is a medical device company focused on continuous glucose monitoring (CGM) systems. The company operates as a single reportable segment, deriving revenue primarily from the sale of disposable sensors and reusable hardware. Key product lines include the G7 system, the G7 15 Day system (launched late 2025), and Stelo (an over-the-counter biosensor launched in August 2024).
Key Financial Metrics
| Metric (in millions, except per share) | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $1,191.9 | $1,036.0 |
| Gross Profit | $750.3 | $589.0 |
| Gross Margin | 62.9% | 56.9% |
| Operating Income | $255.3 | $133.7 |
| Net Income | $199.5 | $105.4 |
| Diluted EPS | $0.51 | $0.27 |
| Operating Cash Flow | $525.6 | $183.8 |
| Cash & Short-term Investments | $2,415.2 | $1,998.7 |
| Long-term Debt (Convertible Notes) | $1,241.8 | $1,240.9 |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 15% year-over-year, driven by increased sales volume of disposable sensors and a net addition of approximately 600,000 to 700,000 customers in 2025. Growth was partially offset by pricing headwinds and rebate eligibility changes.
- Margin Expansion: Gross margin improved to 62.9% from 56.9%, attributed to manufacturing efficiencies, higher production volumes, and better absorption of fixed costs.
- Profitability Surge: Operating income rose 91% and Net Income rose 89%. This was fueled by revenue growth and controlled R&D expenses, which remained flat year-over-year.
- Expense Increases: Selling, General, and Administrative (SG&A) expenses increased 13% ($39.6 million), primarily due to higher compensation costs ($15.9 million) and increased marketing investments ($15.1 million).
- Cash Flow: Operating cash flow surged 186% to $525.6 million, driven by a $94.1 million increase in net income and favorable changes in working capital, specifically a $124.6 million decrease in accounts receivable.
Guidance, Outlook, and Risks
Outlook and Commentary: Management expects cash from operations to fluctuate based on working capital needs and capital deployment. The company anticipates significant capital expenditures in the coming year for manufacturing facility development. No specific numerical guidance for future quarters was provided in this text, though management noted the first quarter is typically seasonal with lower sales due to U.S. insurance deductible resets.
Risks and Contingencies:
- Litigation: The company is facing multiple legal challenges, including securities class actions regarding revenue guidance and device accuracy (G6/G7), as well as derivative actions. The company states it cannot reasonably estimate the ultimate outcome of these matters.
- Debt: The company has $1.25 billion in senior convertible notes due in May 2028. While no principal payments are due prior to maturity, conversion rights could be triggered based on stock price performance.
- Regulatory & Market: Risks include the emergence of competing technologies, delays in regulatory approvals, and third-party reimbursement changes.
Investor Verification Checklist
- Customer Growth vs. Pricing: Verify the sustainability of the 600k-700k net customer additions against the noted pricing headwinds and rebate pressures.
- Litigation Exposure: Monitor the status of the securities class actions and G6/G7 product liability suits, as outcomes could materially impact financial condition.
- Inventory Levels: Review the $693.6 million inventory balance and the $38.6 million in excess/obsolete inventory charges to assess supply chain efficiency.
- Convertible Note Conversion: Track the stock price relative to the $162.41 conversion price of the 2028 Notes to assess potential dilution or cash repayment obligations.
- Share Repurchase Program: Note that no shares were repurchased in Q1 2026 under the $750 million program authorized in April 2025; verify future utilization plans.